Staccato Alprazolam and Photoparoxysmal Response
| Condition | Epilepsy |
|---|---|
| Phase | Phase 2 |
| Sponsor | Nova Pneuma Inc. |
| Status | Completed |
| Enrollment | 5 participants |
| Interventions | A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo |
| Start date | Jan, 2015 |
| Completion date | Jul, 2016 |
| Results posted | Aug 10, 2021 |
Summary
The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.
Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)
| Inhaled Placebo | -0.2 Number of frequency steps |
|---|---|
| Staccato Alprazolam, 0.5 mg | -4.4 Number of frequency steps |
| Staccato Alprazolam, 1 mg | -5.2 Number of frequency steps |
| Staccato Alprazolam, 2 mg | -4.8 Number of frequency steps |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner